Abstract | OBJECTIVE: METHODS: RESULTS: Four patients (33.3%) achieved partial remission and 8 patients (66.7%) had stable disease. The median remission duration was 3.5 months (2-5 months). HCPT treatment as a single agent resulted in mild side effects. Myelosuppression and digestive disorders were found as the main adverse events in the combined chemotherapy group. No chemotherapy related deaths were found. CONCLUSIONS:
HCPT is safe and effective in the treatment of recurrent or refractory neuroblastoma. The toxicities of HCPT are tolerable. The long-term efficacy of HCPT warrants further research.
|
Authors | Zhe-Feng Yuan, Yong-Min Tang, Hua Song, Shu-Wen Shi, Shi-Long Yang, Bin-Hua Pan, Fen-Ying Zhao |
Journal | Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
(Zhongguo Dang Dai Er Ke Za Zhi)
Vol. 11
Issue 5
Pg. 361-3
(May 2009)
ISSN: 1008-8830 [Print] China |
PMID | 19470257
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- 10-hydroxycamptothecin
- Camptothecin
|
Topics |
- Adolescent
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(analogs & derivatives, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Male
- Neuroblastoma
(drug therapy)
- Recurrence
|